Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 3/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20216757 | 0.83 | IMPDH2 (0.47) | — | |
| SCHEMBL12663538 | 0.82 | POLB (0.53) | POLBNSD2ABL1PPARGRIN1 | |
| SCHEMBL371638 | 0.81 | CTSV (0.61) | POLBNSD2ABL1PPARGRIN1 | |
| SCHEMBL4475229 | 0.81 | CTSV (0.61) | POLBNSD2ABL1PPARGRIN1 | |
| SCHEMBL5040429 | 0.79 | ALDH1A1 (0.60) | POLB | |
| SCHEMBL27567115 | 0.78 | ALDH1A1 (0.45) | POLBMTNR1ACTSVCTSLPTGER1 | |
| Nequinate SCHEMBL1509158 | 0.77 | ALDH1A1 (0.52) | POLBMTNR1A | |
| Nequinate SCHEMBL29365503 | 0.77 | ALDH1A1 (0.52) | POLBMTNR1A | |
| SCHEMBL6431029 | 0.76 | IMPDH2 (0.50) | POLBNSD2ABL1PPARGRIN1 | |
| SCHEMBL1894604 | 0.76 | ALDH1A1 (0.45) | POLBCTSVCTSLPTGER1SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| EP-0994846-A1 | METHOD FOR PREPARING 4-(ALKYL)-3-ALKOXY-ANILINE COMPOUNDS | MERIAL (FR) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998057921-A1 | METHOD FOR PREPARING 4-(ALKYL)-3-ALKOXY-ANILINE COMPOUNDS | MERIAL (FR) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | POLB 4789/4885MTNR1A 109/4885NSD2 3029/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | POLB 4789/4885MTNR1A 109/4885NSD2 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.